

Familial Breast Cancer GC2 minutes

Familial Breast Cancer update – guideline committee meeting 2 minutes

Date: 27/02/2026

Location: Virtual

Minutes: Final

Committee members present:		
Alison Cameron	Chair	Present for items 1-10
Helen Hanson	Clinical Geneticist	Present for items 1-7
Zoe Kemp	Clinical Geneticist	Present for items 1-10
Sarah Pugh	Genetic Counsellor	Present for items 1-10
Kathryn Rigby	Breast Surgeon	Present for items 7-9
Tamsin Sargeant	Lay member	Present for items 1-10
Hannah Seabrook	Clinical Psychologist	Present for items 1-8

In attendance NICE:		
Sarah Boyce	Senior Technical Analyst	Present for items 1-10
Danielle Conroy	Project Manager	Present for items 1-10
Lina Ford	Technical Analyst	Present for items 1-10
Gareth Haman	Senior Guidance Content Designer	Present for items 1-10
Marie Harrisingh	Topic Lead	Present for items 1-10
Tzujung Lai	Health Economist	Present for items 1-10
Yolanda Martinez	Technical Analyst	Present for items 1-10
Agnesa Mehmeti	Technical Analyst	Present for items 1-10
Eric Slade	Health Economics Adviser	Present for items 1-10
Adam Storrow	Resource Impact	Present for items 4-10

Apologies:	
Victoria Carter	Implementation Lead, NICE
Kay Davies-Crowley	Advanced Nurse Specialist, committee
Rachael Griffin	Co-opted Lay member, committee
Sadaf Haque	General Practitioner, committee
Ashley Hurst	Lay member, committee
Liz Sherwin	Clinical Oncologist, committee

1. Welcome, Introductions and apologies

The Chair, Alison Cameron (AC) welcomed the committee members and NICE attendees to the 2nd committee meeting for the NICE Familial Breast Cancer guideline update which will focus on initial assessment, genetic testing and risk reducing mastectomy.

AC informed attendees that apologies had been received as noted above and the minutes from committee meeting 1 were checked and agreed to be an accurate record.

2. Declaration of interests

AC asked all committee members to verbally declare any new interests.

No new interests were declared.

AC confirmed that there are no recorded interests which are relevant to the day's discussion.

3. Reminder of scope and meeting aims

The Chair introduced Lina Ford (LF), Technical Analyst who provided the committee with a reminder of the scope of this guideline update and outlined the aims of the meeting.

4. RQ5: effectiveness of risk-reducing mastectomy in people at increased risk of heritable breast cancer:

- **Methods recap**

LF then provided a summary of the methods used for the evidence review for risk reducing mastectomy for people with and without a personal history of breast cancer in advance of presenting the evidence later in the meeting.

The Chair thanks LF for her input.

5. Health economics discussion:

- **Outstanding issues on HE plan**
- **HE model**

The Chair introduced Eric Slade (ES), Health Economics Adviser, who provided an update on the economics for this update.

The committee provided their expert input on several outstanding queries on the health economics plan, including prioritisation of genes to model and age cut-offs for offering genetic testing and risk reducing surgery.

ES presented an overview of the proposed health economic model. The committee had the opportunity to discuss the proposed model structure as a group and ask for any clarifications. The committee also discussed various model assumptions and data sources, including age- and gene-specific cancer risks, genetic testing uptake in

relatives, the effectiveness of surveillance and risk reducing surgery, and cost inputs.

The Chair thanked ES and the committee for their input.

6. Outstanding protocol issues

The Chair introduced Sarah Boyce (SB), Senior Technical Analyst, who asked for committee input on several outstanding queries on the remaining review protocols.

The committee had the opportunity to discuss as a group and offer their expert input on questions relating to population, outcomes and their timepoints.

The NICE team will make edits to the review protocols based on committee's discussion and decisions today.

7. RQ5: effectiveness of risk-reducing mastectomy in people at increased risk of heritable breast cancer:

- **Presentation of clinical evidence**
- **Presentation of cost effectiveness evidence**
- **Committee discussion of evidence**

LF, Technical Analyst presented the clinical evidence for the effectiveness of risk reducing mastectomy for people with and without a personal history of breast cancer.

The committee discussed the results including whether they reflected what they would see in clinical practice, quality of the evidence and benefits vs harms.

The Chair then introduced Tzujung Lai (TL), Health Economist, who presented the existing cost effectiveness evidence for risk reducing mastectomy.

The committee had the opportunity to ask questions and discuss as a group.

The Chair thanked LF and TZ for their presentations.

8. Equality and health inequality considerations

SB, Senior Technical Analyst, introduced the equality and health inequalities assessment for this update and highlighted key points relating to risk reducing mastectomy including age, religion and beliefs, gender reassignment and pregnancy and maternity.

The committee were reminded to keep in mind health equity and potential health inequalities when drafting recommendations in this area.

The Chair thanked SB for her input.

9. Introduction to recommendation drafting and drafting of recommendations

The Chair introduced Marie Harrisingh (MH), Topic Lead, who provided an introduction on drafting NICE recommendations before initiating committee

discussion.

Taking input from the committee to draft the initial wording, the NICE team were able to draft recommendations for risk reducing mastectomy that would be taken away for further edits.

The Chair thanked MH and the committee for their input.

10. AOB and close

AC summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, AC brought the meeting to a close.

Date of next meeting: 9th April 2026

Location of next meeting: Virtual